Topical Bioequivalence Based On DPK Should Be Product Specific - PhRMA
Executive Summary
Dermatopharmacokinetic testing to demonstrate bioavailability/bioequivalence should only be used on a case-by-case basis for topical products, the Pharmaceutical Research & Manufacturers of America suggested in Aug. 17 comments on FDA's draft guidance for topical dermatological products.